Psychopharmacology

, Volume 99, Supplement 1, pp S6–S12 | Cite as

Biochemical and behavioural properties of clozapine

  • D. M. Coward
  • A. Imperato
  • S. Urwyler
  • T. G. White
Article

Abstract

The selection and early development of clozapine was based upon its gross behavioural, arousal-inhibiting, sleep-promoting, and caudate spindle-prolonging properties. Compared to classical neuroleptics, clozapine causes only a short-lasting elevation of plasma prolactin levels, elevates both striatal homovanillic acid and dopamine content, is devoid of marked apomorphine-inhibitory or cataleptogenic activity and fails to induce supersensitivity of striatal dopaminergic systems after chronic administration. Clozapine's intrinsic anticholinergic activity, while stronger than that of other neuroleptic agents, does not appear to underlie either its failure to induce tardive dyskinesias or its superior antipsychotic activity. Furthermore, the overlap between clozapine and several classical neuroleptics with regard to alpha-adrenergic-, serotonin- and histamine-blocking activity makes it unlikely that one or more of these properties is the key to its atypical characteristics. More recent findings show that clozapine and classical neuroleptics differ with regard to their indirect effects on nigral GABA-ergic mechanisms implicated in the induction of tardive dyskinesias and, possibly in keeping with this, that clozapine and similar agents exhibit preferential blockade of D-1 dopamine receptors in the whole animal. Such an action of clozapine in man could well explain both its low EPS liability and, in some subjects, its superior antipsychotic activity.

Key words

Clozapine D-1 Blockade Behavioural effects 

References

  1. Andersen PH (1988) Comparison of the pharmacological characteristics of [3-H]SCH 23390 binding to dopamine receptors in vivo in mouse brain. Eur J Pharmacol 146:113–120Google Scholar
  2. Andersen PH, Nielsen EB, Gronvald FC, Braestrup C (1986) Some atypical neuroleptics inhibit [3-H]SCH 23390 binding in vivo. Eur J Pharmacol 120:143–144Google Scholar
  3. Angst J, Bente D, Berner P, Heiman H, Helmchen H, Hippius H (1971) Das klinische Wirkungsbild von Clozapin (Untersuchung mit dem AMP-System). Pharmakopsychiatry 4:201–211Google Scholar
  4. Arnt J, Scheel-Krüger J (1980) Intranigral GABA antagonists produce dopamine-independent biting in rats. Eur J Pharmacol 62:51–61Google Scholar
  5. Arnt J, Hyttel J, Bach-Lauritsen T (1986) Further studies on the mechanism behind scopolamine-induced reversal of anti-stereotypic and cataleptogenic effect of neuroleptics in rats. Acta Pharmacol Toxicol 59:319–324Google Scholar
  6. Balsara JJ, Jadhav JH, Chandorkar AG (1979a) Effects of drugs influencing central serotoninergic mechanisms on haloperidol-induced catalepsy. Psychopharmacology 62:67–69Google Scholar
  7. Balsara JJ, Jadhav JH, Muley MP, Chandorkar AG (1979b) Effect of drugs influencing central 5-hydroxytryptaminergic mechanisms on morphine-induced catalepsy in the rat. J Pharm Pharmacol 31:255–257Google Scholar
  8. Bowers MB, Rozitis A (1976) Brain homovanillic acid: changes over time with antipsychotic drugs. Eur J Pharmacol 39:109–115Google Scholar
  9. Boyson SJ, McGonigle P, Molinoff PB (1986) Quantitative autoradiographic localisation of the D-1 and D-2 subtypes of dopamine receptors in rat brain. J Neurosci 6:3177–3188Google Scholar
  10. Boyson SJ, McGonigle P, Luthin GR, Wolfe BB, Molinoff PB (1988) Effects of chronic administration of neuroleptic and anticholinergic agents on the densities of D-2 dopamine and muscarinic cholinergic receptors in rat striatum. J Pharmacol Exp Ther 244:987–993Google Scholar
  11. Broekkamp CL, LePichon M, Lloyd KG (1984) Akinesia after locally-applied morphine near the nucleus raphe pontis of the rat. Neurosci Lett 50:313–318Google Scholar
  12. Broekkamp CLE, Oosterlo SK, Berendsen HHG, van Delft AML (1988) Effect of metergoline, fenfluramine and 8-OHDPAT on catalepsy induced by haloperidol or morphine. Naunyn-Schmiedeberg's Arch Pharmacol 338:191–195Google Scholar
  13. Carter CJ, Pycock CJ (1977) Possible importance of 5-hydroxytryptamine in neuroleptic-induced catalepsy in rats. Br J Pharmacol 60:267PGoogle Scholar
  14. Carvey PM, Hitri A, Goetz CG, Tanner CM, Klawans HL (1988) Concurrent treatment with benztropine and haloperidol attenuates development of behavioral hypersensitivity but not dopamine receptor proliferation. Life Sci 42:2207–2215Google Scholar
  15. Chiodo LA, Bunney BS (1983) Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci 3:1607–1619Google Scholar
  16. Chiodo LA, Bunney BS (1985) Possible mechanisms by which repeated clozapine administration differentially affects the activity of two subpopulations of midbrain dopamine neurons. J Neurosci 5:2539–2544Google Scholar
  17. Creese I, Burt DR, Snyder S (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192:481–483Google Scholar
  18. Coward DM (1982) Classical and non-classical neuroleptics induce supersensitivity of nigral GABA-ergic mechanisms in the rat. Psychopharmacology 78:180–184Google Scholar
  19. De Keyser J, Claeys A, De Backer J-P, Ebinger G, Roels F, Vauquelin G (1988) Autoradiographic localization of D-1 and D-2 receptors in the human brain. Neurosci Lett 91:142–147Google Scholar
  20. Farde L, Wiesel F-A, Halldin C, Sedvall G (1988a) Central D2-dopamine receptor occupancy in schizophrenic patients treated with anti-psychotic drugs. Arch Gen Psychiatry 45:71–76Google Scholar
  21. Farde L, Wiesel F-A, Nordstrom A-L, Sedvall G (1988b) PET examination of human D1- and D2-dopamine receptor characteristics. Abstracts of the XVIth C.I.N.P. Congress, Munich. Psychopharmacology [Suppl] 96:79Google Scholar
  22. Frey JM, Ticku MK, Huffman RD (1987) GABAergic supersensitivity within the pars reticulata of the rat substantia nigra following chronic haloperidol administration. Brain Res 425:73–84Google Scholar
  23. Gale K (1980) Chronic blockade of dopamine receptors by antischizophrenic drugs enhances GABA binding in substantia nigra. Nature 283:569–570Google Scholar
  24. Gerlach J (1977) The relationship between parkinsonism and tardive dyskinesia. Am J Psychiatry 143:781–784Google Scholar
  25. Gross H, Langer E (1966) Das Wirkungsprofil eines chemisch neuartigen. Breitbandneuroleptikums der Dibenzodiazepingruppe. Wien Med Wochenschr 116:814–816Google Scholar
  26. Gunne L-M, Haggstrom J-E (1983) Reduction of nigral glutamic acid decarboxylase in rats with neuroleptic-induced dyskinesia. Psychopharmacology 81:191–194Google Scholar
  27. Gunne L-M, Haggstrom J-E, Sjoquist B (1984) Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis. Nature 309:347–349Google Scholar
  28. Hess EJ, Norman AB, Creese I (1988) Chronic treatment with dopamine receptor antagonists: behavioural and pharmacological effects on D-1 and D-2 dopamine receptors. J Neurosci 8:2361–2370Google Scholar
  29. Imperato A, Angelucci L (1988) Effects of the atypical neuroleptics clozapine and fluperlapine on the in vivo dopamine release in the dorsal striatum and in the prefrontal cortex. Abstracts of the XVIth C.I.N.P. Congress, Munich. Psychopharmacology [Suppl] 96:79Google Scholar
  30. Kane J, Honigfeld G, Singer J, Meltzer HY (1988) Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 45:789–796Google Scholar
  31. Klawans HL (1973) The pharmacology of tardive dyskinesias. Am J Psychiatry 130:82–86Google Scholar
  32. Maidment NT, Marsden CA (1987) Repeated atypical neuroleptic administration: effects on central dopamine metabolism monitored by in vivo voltammetry. Eur J Pharmacol 136:141–149Google Scholar
  33. Mao CC, Cheney DL, Marco E, Revuelta A, Costa E (1977) Turnover times of gamma-butyric acid and acetylcholine in nucleus caudatus, nucleus accumbens, globus pallidus and substantia nigra: effects of repeated administration of haloperidol. Brain Res 132:375–379Google Scholar
  34. Meltzer HY, Daniels S, Fang VS (1975) Clozapine increases rat serum prolactin levels. Life Sci 17:339–342Google Scholar
  35. Meltzer HY, Nash JF, Koenig JI, Gudelsky GA (1986) Clozapine: neuroendocrine studies of an atypical neuroleptic. Clin Neuropharmacol [Suppl 4] 9:316–318Google Scholar
  36. Memo M, Kleinman JE, Hanbauer I (1983) Coupling of dopamine D-1 recognition sites with adenylate cyclase in nucleus accumbens and caudatus of schizophrenics. Science 221:1304–1307Google Scholar
  37. Nauta WHJ, Smith GP, Faull RLM, Domesick VB (1978) Efferent connections and nigral afferents of the nucleus accumbens septi in the rat. Neuroscience 3:385–401Google Scholar
  38. Olianas MC, De Montis GM, Mulas G, Tagliamonte A (1978) The striatal dopaminergic function is mediated by the inhibition of a nigral, non-dopaminergic system via a striato-nigral GABAergic pathway. Eur J Pharmacol 49:233–241Google Scholar
  39. Redgrave P, Dean P, Donohoe TP, Pope SG (1980) Superior colliculus lesions selectively attenuate apomorphine-induced oral stereotypy: a possible role for the nigrotectal pathway. Brain Res 196:541–546Google Scholar
  40. Sarnek J, Baran L (1975) The effect of 5-hydroxytryptamine synthesis inhibitors on neuroleptic-induced catalepsy in rats. Arch Immunol Ther Exp 23:511–516Google Scholar
  41. Sayers AC, Buerki H-R, Ruch W, Asper H (1975) Neuroleptic-induced hypersensitivity of striatal dopamine receptors in the rat as a model of tardive dyskinesias. Effects of clozapine, loxapine and chlorpromazine. Psychopharmacologia 41:97–104Google Scholar
  42. Sayers AC, Buerki H-R, Ruch W, Asper H (1976) Anticholinergic properties of antipsychotic drugs and their relation to extrapyramidal side-effects. Psychopharmacology 51:15–22Google Scholar
  43. Scheel-Krüger J, Magelund G, Olianas M, Arnt J, Christensen AV (1981) GABA: an important moderator and mediator of dopamine-dependent behaviours. Adv Biosci 31:31–41Google Scholar
  44. Seeman P, Lee T, Chau-Wong M, Wong K (1976) Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261:717–719Google Scholar
  45. Shippenberg TS, Herz A (1988) Motivational effects of opioids: influence of D-1 versus D-2 receptor antagonists. Eur J Pharmacol 151:233–242Google Scholar
  46. Snyder S, Greenberg D, Yamamura HI (1974) Antischizophrenic drugs and brain cholinergic receptors. Arch Gen Psychiatry 31:58–61Google Scholar
  47. Stevens JR (1973) An anatomy of schizophrenia? Arch Gen Psychiatry 29:177–189Google Scholar
  48. Stevens JR, Wilson K, Foote W (1974) GABA blockade, dopamine and schizophrenia: experimental studies in the cat. Psychopharmacologia 39:105–119Google Scholar
  49. Stille G, Lauener H, Eichenberger E (1971) The pharmacology of 8-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine (clozapine). Il Pharmacol 26:603–625Google Scholar
  50. Stoof JC, Verheijden PFHM (1986) D-2 receptor stimulation inhibits cyclic AMP formation brought about by D-1 receptor stimulation in rat neostriatum but not nucleus accumbens. Eur J Pharmacol 129:205–206Google Scholar
  51. Tarsy D, Baldessarini RJ (1977) The pathophysiologic basis of tardive dyskinesias. Biol Psychiatry 12:431–450Google Scholar
  52. Vidali M, Fregnan GB (1979) Effect of different CNS-active drugs on the catalepsy induced by neuroleptics. Curr Ther Res 25:544–556Google Scholar
  53. Waddington JL (1986) Behavioural correlates of the actions of selective dopamine D-1 receptor antagonists: impact of SCH 23390 and SKF 83566, and functionally interactive D-1:D-2 receptor systems. Biochem Pharmacol 35:3661–3667Google Scholar
  54. White FJ, Wang RY (1983) Comparison of the effects of chronic haloperidol treatment on A9 and A10 dopamine neurons in the rat. Life Sci 32:983–993Google Scholar

Copyright information

© Springer-Verlag 1989

Authors and Affiliations

  • D. M. Coward
    • 1
  • A. Imperato
    • 2
  • S. Urwyler
    • 1
  • T. G. White
    • 1
  1. 1.Sandoz Research Institute Berne LtdBerneSwitzerland
  2. 2.Institute of PharmacologyUniversity “La Sapienza”RomeItaly

Personalised recommendations